News from eisai inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 31, 2021, 08:08 ET Eisai And Advocacy Leaders Team Up To Launch Spot Her - An Initiative That Empowers Women To Help Spot The Signs Of Endometrial Cancer

Eisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire...

Mar 10, 2021, 08:08 ET Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer

Eisai will present two abstracts at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer, March 19-25 (#SGOMtg)....

Mar 05, 2021, 08:52 ET Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company's robust ...

Feb 02, 2021, 14:39 ET Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a...

Jan 27, 2021, 08:08 ET Eisai to Present Investigational Data on LENVIMA® (lenvatinib) Based Combination Therapies in Renal Cell Carcinoma at the 2021 Genitourinary Cancers Symposium

Eisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These investigational data...

Jan 20, 2021, 07:55 ET Dr. Richard Woodman Appointed Chief Clinical Officer of the Oncology Business Group at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Dr. Richard Woodman as Chief Clinical ...

Jan 11, 2021, 08:08 ET Eisai to Present Data on LENVIMA® (lenvatinib) Monotherapy and in Combination with KEYTRUDA® (pembrolizumab) in Multiple Cancer Types at the 2021 Gastrointestinal Cancers Symposium

Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from...

Dec 08, 2020, 07:38 ET #ThisIsMBC Perseverance Campaign from Eisai and METAvivor Captures the Joys, Difficulties and Realities Faced by People Living with Metastatic Breast Cancer

Eisai Inc. and METAvivor today announced the launch of Perseverance, a new initiative of the #ThisIsMBC campaign. Perseverance showcases imagery of a ...

Dec 07, 2020, 10:15 ET Eisai Presents Long-Term Seizure Freedom And Real-World Data Related To Anti-Epileptic Drug FYCOMPA® At The AES 2020 Annual Meeting

Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2020 American Epilepsy...

Dec 01, 2020, 12:21 ET Eisai To Present New Seizure Freedom And Real-World Clinical Practice Data Evaluating FYCOMPA® Across Diverse Patient Types At Upcoming AES 2020 Annual Meeting

Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 74th American Epilepsy Society ...

Nov 20, 2020, 18:00 ET Eisai Announces New Investigational Data from Study 211 Evaluating the Starting Dose of LENVIMA® (lenvatinib) in Differentiated Thyroid Cancer at ESMO Asia 2020

Eisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor ...

Nov 19, 2020, 21:10 ET Eisai to Present New Investigational Data on LENVIMA® (lenvatinib) in Thyroid Cancer and Osteosarcoma at ESMO Asia 2020

Eisai announced today the presentation of three abstracts including investigational data in thyroid cancer and osteosarcoma at the European Society...

Nov 07, 2020, 07:00 ET Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA® (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020

Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once...

Nov 05, 2020, 19:00 ET Eisai Announces Investigational Data Highlighting LENVIMA® (lenvatinib) Based Combination Therapy in Patients With Renal Cell Carcinoma at IKCS 2020

Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from...

Nov 02, 2020, 12:02 ET Eisai to Present Latest Alzheimer's Disease Pipeline Research at Digital CTAD 2020, Including BAN2401, Anti-Microtubule Binding Region Tau Antibody, and Lemborexant Data

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's...

Sep 30, 2020, 09:02 ET Eisai Initiates Phase 3 MOMENTUM 1 Clinical Trial (Study 304) of Lorcaserin in Dravet Syndrome

Eisai Inc. announced today that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase 3 clinical...

Sep 10, 2020, 19:30 ET Eisai to Present New Data Highlighting KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and Eribulin Platform at ESMO 2020

Eisai will present two late breakers and 10 e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, ...

Aug 28, 2020, 11:31 ET Eisai Presents New Analyses from Phase 3 Studies of DAYVIGO™ (lemborexant) CIV for the Treatment of Insomnia in Adult Patients at Virtual SLEEP 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced findings from several post hoc analyses of DAYVIGO™ from the Phase ...

Aug 24, 2020, 08:10 ET Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO™ (lemborexant) CIV, at the SLEEP 2020 Virtual Conference

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO™ (lemborexant) CIV research at the...

Aug 11, 2020, 09:05 ET Eisai Pharmaceuticals to Make the ON3 Next-Generation Life-Science and Lifestyle Campus its U.S. Headquarters

Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., (based in Tokyo, Japan) announced...

Aug 11, 2020, 08:08 ET Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer

Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available...

Jul 24, 2020, 08:46 ET Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AAIC 2020, Including BAN2401 and Lemborexant Data and a Biomarker Symposium

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and information from the company's...

Jun 01, 2020, 08:05 ET Eisai Announces U.S. Availability of DAYVIGO® (lemborexant) CIV, a New Treatment Option for Adults With Insomnia

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO® (lemborexant) CIV for the treatment...

May 29, 2020, 08:35 ET Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in...

May 13, 2020, 19:44 ET Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, including KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin mesylate)

Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology's ASCO20 Virtual...